Suppr超能文献

金顶侧耳多糖通过抑制肠道病毒 71 复制和病毒 3D 聚合酶发挥作用。

Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid.

机构信息

Department of Biological Science and Technology, National Chiao Tung University, Hsin-Chu, Taiwan.

出版信息

J Antimicrob Chemother. 2010 Apr;65(4):676-83. doi: 10.1093/jac/dkp502. Epub 2010 Jan 20.

Abstract

OBJECTIVES

Enterovirus 71 (EV71) causes serious diseases in humans. The aim of this study was to examine the effects of aurintricarboxylic acid (ATA) on EV71 replication and to explore the underlying mechanism.

METHODS

To measure the activity of ATA in inhibiting the cytopathic effect (CPE) of EV71, a cell-based neutralization (inhibition of virus-induced CPE) assay was performed. The effect of ATA was further confirmed using plaque reduction and viral yield reduction assays. A time of addition assay was performed to identify the mechanisms of ATA's anti-EV71 activity. We examined the effects of ATA on the following key steps involved in virus replication: (i) translation of the internal ribosomal entry site (IRES)-mediated viral polyprotein; (ii) the proteolytic activity of viral proteases 2A and/or 3C; and (iii) the viral 3D RNA-dependent RNA polymerase (RdRp) activity.

RESULTS

In this study, ATA was found to be a potent inhibitor of the replication of EV71. In the antiviral neutralization assay, ATA exhibited inhibitory activity against EV71 (TW/4643/98) and EV71 (TW/2231/98). Plaque assay further demonstrated that ATA inhibited EV71 replication with an EC(50) (effective concentration at which 50% of plaques were removed) of 2.9 microM. Studies on the mechanism of action revealed that ATA targets the early stage of the viral life cycle after viral entry. ATA was able to inhibit the RdRp activity of EV71, while neither the IRES-mediated translation of viral polyprotein nor the viral 3C protease activity was affected.

CONCLUSIONS

Overall, the findings in this study suggest that ATA is able to effectively inhibit EV71 replication through interfering with the viral 3D polymerase.

摘要

目的

肠道病毒 71 型(EV71)可引起人类严重疾病。本研究旨在探讨金顶侧耳多糖(ATA)对 EV71 复制的影响及其作用机制。

方法

采用细胞病变抑制法(抑制病毒诱导的细胞病变效应)测定 ATA 抑制 EV71 细胞病变效应(CPE)的活性。采用空斑减少和病毒产量减少试验进一步证实 ATA 的作用。采用时效试验确定 ATA 抗 EV71 活性的作用机制。我们研究了 ATA 对病毒复制的以下关键步骤的影响:(i)内部核糖体进入位点(IRES)介导的病毒多蛋白翻译;(ii)病毒蛋白酶 2A 和/或 3C 的蛋白水解活性;和(iii)病毒 3D RNA 依赖性 RNA 聚合酶(RdRp)活性。

结果

本研究发现 ATA 是 EV71 复制的有效抑制剂。在抗病毒中和试验中,ATA 对 EV71(TW/4643/98)和 EV71(TW/2231/98)均表现出抑制活性。空斑试验进一步表明,ATA 以 2.9 μM 的 EC50(可去除 50%斑块的有效浓度)抑制 EV71 复制。作用机制研究表明,ATA 靶向病毒进入后的病毒生命周期早期。ATA 能够抑制 EV71 的 RdRp 活性,而不影响 IRES 介导的病毒多蛋白翻译或病毒 3C 蛋白酶活性。

结论

总的来说,本研究结果表明,ATA 通过干扰病毒 3D 聚合酶,能够有效抑制 EV71 的复制。

相似文献

10
Inhibition of enterovirus 71 by adenosine analog NITD008.腺苷类似物NITD008对肠道病毒71型的抑制作用
J Virol. 2014 Oct;88(20):11915-23. doi: 10.1128/JVI.01207-14. Epub 2014 Aug 6.

引用本文的文献

1
3
Drug Repurposing for Therapeutic Discovery against Human Metapneumovirus Infection.药物重定位用于治疗人类偏肺病毒感染的治疗发现。
Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0100822. doi: 10.1128/aac.01008-22. Epub 2022 Sep 12.
4
Enterovirus A71 antivirals: Past, present, and future.肠道病毒A71抗病毒药物:过去、现在与未来。
Acta Pharm Sin B. 2022 Apr;12(4):1542-1566. doi: 10.1016/j.apsb.2021.08.017. Epub 2021 Aug 20.
8
Enterovirus D68 Antivirals: Past, Present, and Future.肠道病毒D68抗病毒药物:过去、现在与未来
ACS Infect Dis. 2020 Jul 10;6(7):1572-1586. doi: 10.1021/acsinfecdis.0c00120. Epub 2020 May 14.
10
Antivirals and vaccines for Enterovirus A71.肠道病毒 A71 的抗病毒药物和疫苗。
J Biomed Sci. 2019 Sep 3;26(1):65. doi: 10.1186/s12929-019-0560-7.

本文引用的文献

6
Aurintricarboxylic acid inhibits influenza virus neuraminidase.金精三羧酸抑制流感病毒神经氨酸酶。
Antiviral Res. 2009 Feb;81(2):123-31. doi: 10.1016/j.antiviral.2008.10.006. Epub 2008 Nov 17.
9
Development of antiviral agents for enteroviruses.肠道病毒抗病毒药物的研发。
J Antimicrob Chemother. 2008 Dec;62(6):1169-73. doi: 10.1093/jac/dkn424. Epub 2008 Oct 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验